20-Feb-2026
No headlines found.
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
Business Wire (Mon, 9-Feb 4:01 PM ET)
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Business Wire (Mon, 24-Nov 4:01 PM ET)
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
Forte Biosciences trades on the NASDAQ stock market under the symbol FBRX.
As of February 20, 2026, FBRX stock price declined to $29.04 with 154,707 million shares trading.
FBRX has a beta of 1.59, meaning it tends to be more sensitive to market movements. FBRX has a correlation of 0.05 to the broad based SPY ETF.
FBRX has a market cap of $363.78 million. This is considered a Small Cap stock.
In the last 3 years, FBRX traded as high as $35.62 and as low as $4.11.
The top ETF exchange traded funds that FBRX belongs to (by Net Assets): VTI, VXF, ATFV, IWC, AVSC.
FBRX has outperformed the market in the last year with a return of +190.1%, while the SPY ETF gained +13.7%. In the last 3 month period, FBRX beat the market returning +55.2%, while SPY returned +4.3%. However, in the most recent 2 weeks FBRX has underperformed the stock market by returning +0.8%, while SPY returned +1.7%.
FBRX support price is $27.28 and resistance is $32.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FBRX shares will trade within this expected range on the day.